Relapsed T-Cell Cancers: CD7 Autologous CAR-T (PA3-17)

This briefing explains what the technology is meant to do, who might be discussed for it, and what it does not replace. It is not medical advice and does not promise tumor shrinkage, functional recovery, or a cure. Eligibility, the receiving hospital, and the bill must be confirmed in writing by that hospital. Do not stop standard treatment unless the specialist agrees.

CD7 is a surface marker on some lymphoid cancer cells. In adults, relapsed or refractory CD7-positive disease includes some acute lymphoblastic leukemia, T-cell lymphoma, and peripheral T-cell lymphoma. After chemotherapy, targeted drugs, or immunotherapy have failed, few options remain.

PA3-17 is described as an autologous CAR-T injection aimed at CD7, placed among exploratory technologies in Lecheng, not a product on pharmacy shelves everywhere. The sequence is leukapheresis, genetic modification, expansion, release testing, possible lymphodepletion after a physician’s decision, then intravenous infusion. CD7 is also on normal T cells, so the target has to deal with injury to those cells. This is not CD19 CAR-T. Dose and nursing cannot be copied from a B-cell lymphoma product.

1. Pathology and immunophenotype must confirm CD7, and tumor burden is measured;
2. Organ function has to tolerate lymphodepletion and infusion;
3. Uncontrolled infection, active bleeding, and severe organ failure stay out;
4. In hospital, CRS, ICANS, blood counts, infection, and tumor burden are monitored;
5. Complete remission and long survival are not guaranteed. Do not stop current cancer treatment on your own.